AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20150299 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-taking behaviors
Number of subjects: 463
Study 17392946 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 17
Study 17392946 — intervention group
Group type: COMPARATOR
Intervention: Wait listed control
Number of subjects: 17
Study 11408508 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705
Study 11408508 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 7705
Study 11408508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 11408508 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (both dosages)
Number of subjects: 7705
Study 9259905 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline pump
Number of subjects: 42
Study 9259905 — intervention group
Group type: COMPARATOR
Intervention: Saline pump
Number of subjects: 42
Study 9259905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 42
Study 8284109 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg s.c. twice weekly for 6 weeks
Number of subjects: 44
Study 8284109 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 44
Study 3565967 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 24
Study 3565967 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 24
Study 31652025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pararectal stoma placement
Number of subjects: 60
Study 31652025 — intervention group
Group type: COMPARATOR
Intervention: Transrectal stoma placement
Number of subjects: 60
Study 29319910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg transdermal)
Number of subjects: 33
Study 29319910 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg oral)
Number of subjects: 33
Study 29319910 — intervention group
Group type: COMPARATOR
Intervention: Mecamylamine (30 mg oral)
Number of subjects: 33
Study 29319910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 28002201 — intervention group
Group type: COMPARATOR
Intervention: TX-004HR 4 μg
Number of subjects: 72
Study 28002201 — intervention group
Group type: COMPARATOR
Intervention: TX-004HR 10 μg
Number of subjects: 72
Study 28002201 — intervention group
Group type: COMPARATOR
Intervention: TX-004HR 25 μg
Number of subjects: 72
Study 28002201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26229448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioaspirin + Aterofisiol
Number of subjects: 214
Study 26229448 — intervention group
Group type: COMPARATOR
Intervention: Cardioaspirin + placebo
Number of subjects: 214
Study 24155873 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise treatment
Number of subjects: 10
Study 22114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficiently controlled asthma
Number of subjects: 720
Study 22114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Strictly controlled asthma
Number of subjects: 720
Study 22114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Strictly controlled asthma based on exhaled nitric oxide
Number of subjects: 720
Study 22114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based asthma monitoring system
Number of subjects: 720
Study 22114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Societal costs (medication, other healthcare, productivity)
Number of subjects: 720
Study 18772602 — intervention group
Group type: EXPERIMENTAL
Intervention: PTRA + IVBT
Number of subjects: 71
Study 18772602 — intervention group
Group type: COMPARATOR
Intervention: PTRA
Number of subjects: 71
Study 16996876 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 16
Study 16996876 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 16
Study 16996876 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 16
Study 16996876 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 16
Study 12887537 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal repair of the thoracic aorta
Number of subjects: 0
Study 12887537 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical repair
Number of subjects: 0
Study 11049956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5, 1, or 2 microg/kg/min)
Number of subjects: 9
Study 11049956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11049956 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.5, 1, or 2 microg/kg/min)
Number of subjects: 9
Study 8849376 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1RI at 1,000 micrograms/m2/day
Number of subjects: 23
Study 8849376 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1RI at smaller doses (125, 250, 500 micrograms/m2/day)
Number of subjects: 23
Study 8849376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8849376 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL‐1RI (all doses)
Number of subjects: 23
Study 1317234 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg p.o.)
Number of subjects: 8
Study 1317234 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg p.o.)
Number of subjects: 8
Study 1317234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31757774 — intervention group
Group type: EXPERIMENTAL
Intervention: ETVAX (5·5 × 10^10 cells, 2·5 × 10^10 cells, or 1·25 × 10^10 cells) with or without dmLT (2·5 μg, 5·0 μg, or 10·0 μg)
Number of subjects: 430
Study 31757774 — intervention group
Group type: EXPERIMENTAL
Intervention: ETVAX with dmLT
Number of subjects: 430
Study 31757774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 31757774 — intervention group
Group type: EXPERIMENTAL
Intervention: ETVAX
Number of subjects: 430
Study 29533716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid composite (Ceram X duo)
Number of subjects: 34
Study 29533716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite (Filtek Supreme XT)
Number of subjects: 34
Study 27556488 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon (WM) puree, 980 mL/day for 2 weeks, containing 0.2 gm/kg carbohydrate
Number of subjects: 20
Study 27556488 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate beverage, 6% carbohydrate, consumed every 15 min during cycling trials
Number of subjects: 20
Study 27556488 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon (WM) puree
Number of subjects: 20
Study 25007060 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and teacher healthy lifestyle role-modeling program
Number of subjects: 28
Study 25007060 — intervention group
Group type: COMPARATOR
Intervention: Attention control safety curriculum (Control)
Number of subjects: 28
Study 25007060 — intervention group
Group type: COMPARATOR
Intervention: Control group (parents)
Number of subjects: 28
Study 25007060 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 28
Study 25007060 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' influence
Number of subjects: 28
Study 22674892 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (lower extremity strengthening, stretching, range of motion, balance and agility, and aerobic exercises)
Number of subjects: 152
Study 22674892 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program
Number of subjects: 152
Study 20728652 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (0.08 g/dl)
Number of subjects: 23
Study 20728652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18439175 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation system (MNS) with an 8‐mm‐tip magnetic catheter for RF ablation (70 degrees C, maximum power 70 W, 90 seconds)
Number of subjects: 26
Study 18439175 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation system (MNS) with an 8‐mm‐tip magnetic catheter for RF ablation
Number of subjects: 26
Study 18439175 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (first 14 patients)
Number of subjects: 26
Study 18439175 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (remaining patients)
Number of subjects: 26
Study 17111709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaste tree fruit (Vitex agnus)
Number of subjects: 19
Study 17111709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale)
Number of subjects: 19
Study 17111709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa
Number of subjects: 19
Study 14522623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 0.05% cream
Number of subjects: 199
Study 14522623 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 1% cream
Number of subjects: 199
Study 14522623 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone butyrate (HCB) 0.1% cream
Number of subjects: 199
Study 10972598 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose of 20 microg/kg followed by infusion of 0.2 microg/kg/min) in low pre-CPB CI group
Number of subjects: 48
Study 10972598 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose of 20 microg/kg followed by infusion of 0.2 microg/kg/min) in high pre-CPB CI group
Number of subjects: 48
Study 10972598 — intervention group
Group type: COMPARATOR
Intervention: Placebo in low pre-CPB CI group
Number of subjects: 48
Study 10972598 — intervention group
Group type: COMPARATOR
Intervention: Placebo in high pre-CPB CI group
Number of subjects: 48
Study 8831437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized interpersonal psychotherapy
Number of subjects: 157
Study 8831437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with nortriptyline
Number of subjects: 157
Study 8831437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 157
Study 1482134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of TIBO (100 mg for 29 days)
Number of subjects: 5
Study 1482134 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of TIBO (100 mg, 200 mg, and 100 mg with probenecid daily for 14 days)
Number of subjects: 5
Study 6531024 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐MOP plus TMP (combination dose)
Number of subjects: 366
Study 6531024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 8‐MOP (0.3 mg/kg)
Number of subjects: 366
Study 6531024 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐MOP or combination group of 8‐MOP plus TMP
Number of subjects: 366
Study 6531024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TMP and psoralen
Number of subjects: 366
Study 6531024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 31909382 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP Block with USG guidance using 0.25% bupivacaine 60 ml (30 ml at each side)
Number of subjects: 30
Study 31909382 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl 60 ml (30 ml at each side) with USG guidance (Control Group)
Number of subjects: 30
Study 29505512 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a past history of hyperglycaemia
Number of subjects: 772
Study 29505512 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle habits and risk factors
Number of subjects: 772
Study 27139477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam plus metronidazole
Number of subjects: 55
Study 27139477 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 55
Study 25194966 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 48
Study 25194966 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 48
Study 23231750 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour between 39⁰/⁷ and 39⁶/⁷ weeks gestation
Number of subjects: 630
Study 23231750 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (awaiting spontaneous onset of labour)
Number of subjects: 630
Study 20227354 — intervention group
Group type: COMPARATOR
Intervention: Test cigarettes (EHCSS or activated carbon filter)
Number of subjects: 0
Study 20227354 — intervention group
Group type: COMPARATOR
Intervention: Stopping smoking
Number of subjects: 0
Study 20227354 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 0
Study 18679600 — intervention group
Group type: EXPERIMENTAL
Intervention: Weicao Capsule (WCC)
Number of subjects: 200
Study 18679600 — intervention group
Group type: COMPARATOR
Intervention: Tongfengding Capsule (Control)
Number of subjects: 200
Study 16003661 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) using treatment-based classification guidelines
Number of subjects: 66
Study 12452739 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide/metformin 2.5/500mg tablets (Glucovance)
Number of subjects: 40
Study 12452739 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide 2.5mg with metformin 500mg (Micronase + Glucophage)
Number of subjects: 40
Study 10086398 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (teacher training, parent education, social competence training)
Number of subjects: 643
Study 10086398 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 643
Study 10086398 — intervention group
Group type: COMPARATOR
Intervention: Late intervention (grades 5 and 6 only)
Number of subjects: 643
Study 7555001 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg) + Diazepam (10 mg)
Number of subjects: 8
Study 7555001 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (250 mg) alone
Number of subjects: 8
Study 2345079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (3 to 30 micrograms/kg)
Number of subjects: 30
Study 2345079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2345079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 30
Study 7437243 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 0
Study 7437243 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium (every 6 h)
Number of subjects: 0
Study 31230925 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-axis approach by two operators
Number of subjects: 100
Study 31230925 — intervention group
Group type: COMPARATOR
Intervention: Long-axis approach by two operators
Number of subjects: 100
Study 30326551 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Dynamic Stretching (SDS)
Number of subjects: 18
Study 30326551 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Dynamic Stretching (FDS)
Number of subjects: 18
Study 28654958 — intervention group
Group type: EXPERIMENTAL
Intervention: FH + WGS group
Number of subjects: 100
Study 28654958 — intervention group
Group type: COMPARATOR
Intervention: FH group
Number of subjects: 100
Study 25362844 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 89
Study 25362844 — intervention group
Group type: COMPARATOR
Intervention: High-dose rate brachytherapy (2×10 Gy) and external beam radiotherapy (25×2 Gy)
Number of subjects: 89
Study 23040208 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate 70 mg once weekly
Number of subjects: 191
Study 23040208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 21555984 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera-Band® Elastic Resistance-Assisted Gait Training
Number of subjects: 16
Study 21555984 — intervention group
Group type: COMPARATOR
Intervention: Conventional Occupational Therapy and Conventional Gait Training
Number of subjects: 16
Study 19300233 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted Vicryl sutures
Number of subjects: 625
Study 19300233 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous polydioxanone suture (PDS)
Number of subjects: 625
Study 19300233 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Monoplus sutures
Number of subjects: 625
Study 17761566 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfinance intervention combined with participatory training on HIV, gender norms, domestic violence, and sexuality.
Number of subjects: 0
Study 17761566 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfinance intervention
Number of subjects: 0
Study 15561795 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized protocol
Number of subjects: 484
Study 15561795 — intervention group
Group type: COMPARATOR
Intervention: Paper-based protocol
Number of subjects: 484
Study 15561795 — intervention group
Group type: COMPARATOR
Intervention: Control group (paper-based)
Number of subjects: 484
Study 15561795 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized group
Number of subjects: 484
Study 15561795 — intervention group
Group type: COMPARATOR
Intervention: First study period (paper-based)
Number of subjects: 484
Study 15561795 — intervention group
Group type: COMPARATOR
Intervention: Third study period (paper-based)
Number of subjects: 484
Study 12150179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain twice daily for 5 days
Number of subjects: 30
Study 12150179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12150179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain twice daily for 5 days (early intervention)
Number of subjects: 30
Study 12150179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (early intervention)
Number of subjects: 30
Study 9477100 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactically guided fine-needle aspiration (SFNA) followed by stereotactically guided core needle biopsy (SCNB)
Number of subjects: 377
Study 9477100 — intervention group
Group type: COMPARATOR
Intervention: Stereotactically guided core needle biopsy (SCNB) only
Number of subjects: 377
Study 9477100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided fine-needle aspiration (USFNA) followed by ultrasonographically guided core needle biopsy (USCNB)
Number of subjects: 377
Study 9477100 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographically guided core needle biopsy (USCNB) only
Number of subjects: 377
Study 8682921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse (Corsodyl)
Number of subjects: 0
Study 8682921 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxycarbonate rinse (Kavosan)
Number of subjects: 0
Study 8682921 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxyborate rinse (Bocasan)
Number of subjects: 0
Study 8682921 — intervention group
Group type: COMPARATOR
Intervention: Saline rinse (negative control)
Number of subjects: 0
Study 1972847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injections of PPD (1 in 1000)
Number of subjects: 21
Study 1972847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injections of streptokinase/streptodornase (20 mu/5 mu per 0.1 ml)
Number of subjects: 21
Study 1972847 — intervention group
Group type: COMPARATOR
Intervention: Saline control solutions
Number of subjects: 21
Study 539651 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (Alodan) and promethazine (Phenergan)
Number of subjects: 96
Study 539651 — intervention group
Group type: COMPARATOR
Intervention: Thalamonal
Number of subjects: 96
Study 29927661 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated dissemination approach
Number of subjects: 24
Study 29927661 — intervention group
Group type: COMPARATOR
Intervention: Traditional dissemination approach
Number of subjects: 24
Study 29927661 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 24
Study 28554606 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPI (interviewer-administered comprehensive health and social risk assessments)
Number of subjects: 750
Study 28554606 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI (self-administered comprehensive health and social risk assessments)
Number of subjects: 750
Study 28554606 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 750
Study 28554606 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPI
Number of subjects: 750
Study 28554606 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 750
Study 25540305 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation
Number of subjects: 7
Study 25540305 — intervention group
Group type: COMPARATOR
Intervention: 130 Hz stimulation
Number of subjects: 7
Study 23432801 — intervention group
Group type: EXPERIMENTAL
Intervention: SP monthly and azithromycin (1 g) twice (AZI-SP)
Number of subjects: 1320
Study 23432801 — intervention group
Group type: EXPERIMENTAL
Intervention: SP monthly (monthly SP)
Number of subjects: 1320
Study 23432801 — intervention group
Group type: COMPARATOR
Intervention: SP (control)
Number of subjects: 1320
Study 20796074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stress (GII)
Number of subjects: 28
Study 20796074 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted feeding (GIII)
Number of subjects: 28
Study 20796074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stress (GIV)
Number of subjects: 28
Study 20796074 — intervention group
Group type: COMPARATOR
Intervention: Control (GI)
Number of subjects: 28
Study 18783417 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate functional loading with occlusal contact or immediate nonfunctional loading without occlusal contact
Number of subjects: 155
Study 18783417 — intervention group
Group type: COMPARATOR
Intervention: One‐stage or two‐stage surgical procedure (control group)
Number of subjects: 155
Study 16709205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin treatment
Number of subjects: 819
Study 16709205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 819